Is Summit Therapeutics Inc. (SMMT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 6.1% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 6.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 2.8% / 33% | 95.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 6.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 2.8% / 33% | 95.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -206.1% | |
| Return on Assets (ROA) | -115.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$323M |
| Free Cash Flow | -$324M |
| Total Debt | $21M |
| Debt-to-Equity | 3.2 |
| Current Ratio | 9.9 |
| Total Assets | $751M |
Price & Trading
| Last Close | $17.26 |
| 50-Day MA | $15.76 |
| 200-Day MA | $19.86 |
| Avg Volume | 2.5M |
| Beta | -1.4 |
|
52-Week Range
$13.83
| |
About Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Summit Therapeutics Inc. (SMMT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Summit Therapeutics Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Summit Therapeutics Inc.'s debt ratio?
Summit Therapeutics Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.8%.
What are Summit Therapeutics Inc.'s key financial metrics?
Summit Therapeutics Inc. has a market capitalization of $12.9B. Return on equity stands at -206.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.